Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aurinia Pharm Ord
(NQ:
AUPH
)
6.810
-0.090 (-1.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aurinia Pharm Ord
< Previous
1
2
3
4
5
6
Next >
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results
January 06, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals
January 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
November 30, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
November 03, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022
October 28, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022
October 27, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022
September 20, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
September 19, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
NASDAQ: AUPH Long Term Investor Alert: Investigation of Potential Wrongdoing at Aurinia Pharmaceuticals Inc.
August 15, 2022
San Diego, CA -- (SBWIRE) -- 08/15/2022 -- Certain directors of Aurinia Pharmaceuticals Inc. are under investigation over possible breaches of fiduciary duties.
Via
SBWire
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
August 04, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
July 26, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
July 25, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
July 22, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance
July 14, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Aurinia Pharmaceuticals Inc. (AUPH) Investors of Class Action and Last Day to Actively Participate
June 13, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
AURINIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
June 11, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
AUPH FINAL DEADLINE TUESDAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 14 Deadline in Securities Class Action - AUPH
June 11, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
NASDAQ:AUPH Investor Notice: Deadline on June 14, 2022 in Lawsuit Against Aurinia Pharmaceuticals Inc.
June 08, 2022
San Diego, CA -- (SBWIRE) -- 06/08/2022 -- The Shareholders Foundation announced that a deadline is coming up on June 14, 2022 in the lawsuit filed for certain investors of Aurinia Pharmaceuticals Inc....
Via
SBWire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
June 03, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPH
May 27, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
May 20, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress
May 16, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
INVESTOR DEADLINE: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AUPH
May 13, 2022
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Shareholder Action Reminder: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
May 11, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.